Literature DB >> 12727832

Intradermal injection, as opposed to subcutaneous injection, enhances immunogenicity and suppresses tumorigenicity of tumor cells.

Bernard Bonnotte1, Michael Gough, Vy Phan, Atique Ahmed, Heung Chong, François Martin, Richard G Vile.   

Abstract

Tumor cell immunogenicity depends heavily upon the microenvironment in which the cells grow. We have compared the tumorigenicity and immunogenicity of the same tumor cells when injected either into the dermis, a tissue containing numerous dendritic cells (DCs), or s.c., at a site which contains only few DCs. After s.c. injection, progressive tumors were constantly obtained, whereas most intradermal injections did not give rise to tumor and immunized animals against additional challenge. We present evidence that the high density of DCs at dermal sites facilitates the capture of tumor antigens and that local inflammation induces maturation of the DCs and their migration into draining lymph nodes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727832

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.

Authors:  Basav N Hangalapura; Dinja Oosterhoff; Tarun Gupta; Jan de Groot; Pepijn G J T B Wijnands; Victor W van Beusechem; Joke den Haan; Thomas Tüting; Alfons J M van den Eertwegh; David T Curiel; Rik J Scheper; Tanja D de Gruijl
Journal:  Vaccine       Date:  2011-01-25       Impact factor: 3.641

Review 2.  Effect of vaccine administration modality on immunogenicity and efficacy.

Authors:  Lu Zhang; Wei Wang; Shixia Wang
Journal:  Expert Rev Vaccines       Date:  2015-08-27       Impact factor: 5.217

3.  Comparison of Models for Bubonic Plague Reveals Unique Pathogen Adaptations to the Dermis.

Authors:  Rodrigo J Gonzalez; Eric H Weening; M Chelsea Lane; Virginia L Miller
Journal:  Infect Immun       Date:  2015-05-04       Impact factor: 3.441

4.  Intradermal application of vitamin D3 increases migration of CD14+ dermal dendritic cells and promotes the development of Foxp3+ regulatory T cells.

Authors:  Ghaith Bakdash; Laura P Schneider; Toni M M van Capel; Martien L Kapsenberg; Marcel B M Teunissen; Esther C de Jong
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

5.  A new approach for skin tumor treatment: from delivery system characterization to in vivo evaluation.

Authors:  Denize Ainbinder; Elka Touitou
Journal:  Drug Deliv Transl Res       Date:  2011-02       Impact factor: 4.617

6.  Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model.

Authors:  J J Ruotsalainen; M U Kaikkonen; M Niittykoski; M W Martikainen; C G Lemay; J Cox; N S De Silva; A Kus; T J Falls; J-S Diallo; F Le Boeuf; J C Bell; S Ylä-Herttuala; A E Hinkkanen; M J Vähä-Koskela
Journal:  Gene Ther       Date:  2014-09-18       Impact factor: 5.250

7.  Optical tomography of MMP activity allows a sensitive noninvasive characterization of the invasiveness and angiogenesis of SCC xenografts.

Authors:  Wa'el Al Rawashdeh; Susanne Arns; Felix Gremse; Josef Ehling; Ruth Knüchel-Clarke; Stefan Kray; Felix Spöler; Fabian Kiessling; Wiltrud Lederle
Journal:  Neoplasia       Date:  2014-03       Impact factor: 5.715

8.  Immunotherapy for advanced prostate cancer.

Authors:  Johannes Vieweg
Journal:  Rev Urol       Date:  2007

9.  The laboratory opossum (Monodelphis domestica) as a natural mammalian model for human cancer research.

Authors:  Zhiqiang Wang; Gene B Hubbard; Fred J Clubb; John L Vandeberg
Journal:  Int J Clin Exp Pathol       Date:  2008-11-06

10.  Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas.

Authors:  Timothy Kottke; Jose Pulido; Jill Thompson; Luis Sanchez-Perez; Heung Chong; Stuart K Calderwood; Peter Selby; Kevin Harrington; Scott E Strome; Alan Melcher; Richard G Vile
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.